以结构为导向的亲和/共价键双驱动抑制剂的设计,针对FBPase的AMP部位
Hongxuan Cao1, Zeyue Huang1, Zheng Liu1
1State Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Journal of medicinal chemistry
|November 9, 2024
概括
新的双驱动抑制剂向果糖-1,6-双酸酶 (FBPase),这是糖尿病和癌症的关键酶. 与C179的共价结合增强了长期的低血糖效应,提供了一个有前途的药物开发策略.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 果糖-1,6-双酸酶 (FBPase) 是癌症和II型糖尿病的重要治疗点.
- 针对AMP全位的现有FBPase抑制剂具有有限的选择性,导致潜在的不良影响.
研究的目的:
- 设计和开发FBPase的新型亲和力/共价键双驱抑制剂.
- 通过向AMP口袋和邻近的半氨酸残留物 (C179) 来提高抑制剂的选择性和有效性.
主要方法:
- 利用了FBPase AMP口袋和C179.9的药理学知识.
- 采用氨酸向反应性弹头屏幕,然后进行结构优化.
- 通过拉下测试和西布洛特测试证实了FBPase在肝细胞中的直接向.
- 通过X射线共晶学和Cov_DOX计算来确定结合机制.
主要成果:
- 设计的双驱抑制剂显示强大的FBPase抑制.
- 射线晶体学揭示了结合和π-π堆叠作为关键的结合相互作用.
- 证实了对C179的共价结合,有助于持续的低血糖效应.
- 抑制剂显示出有希望的长期低血糖效应.
结论:
- 亲和/共价键双驱动抑制剂是FBPase向药物开发的有希望的策略.
- 开发的抑制剂为治疗与FBPase活性相关的疾病提供了有效的方法.
- 这项研究为开发针对AMP相关蛋白的新疗法提供了基础.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
10:28A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
Published on: August 17, 2019
9.5K
相关概念视频
Enzymes
80.8K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
80.8K
Structure-Activity Relationships and Drug Design
597
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
597
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
